Skip to main content

Advertisement

Table 2 Change from Baseline in sleep measures at week 12

From: Improvement of sleep in patients with chronic idiopathic/spontaneous urticaria treated with omalizumab: results of three randomized, double-blind, placebo-controlled studies

Scale ASTERIA I ASTERIA II GLACIAL
Placebo Omalizumab 75 mg Omalizumab 150 mg Omalizumab 300 mg Placebo Omalizumab 75 mg Omalizumab 150 mg Omalizumab 300 mg Placebo Omalizumab 300 mg
MOS-Sleep Scale, SPI-II, n 63 67 63 72 70 70 70 73 62 217
 Mean (SD) −1.7 (18.0) −14.4 (18.6) −11.8 (20.6) −18.1 (21.6)* −10.8 (16.7) −15.5 (20.0) −16.4 (15.4)* −16.8 (19.4)* −13.4 (15.8) −19.0 (20.5)***
UPDD Weekly Sleep Interference Score, n 62 64 63 73 69 68 73 74 67 214
 Mean (SD) −5.0 (5.3) −7.0 (5.6) −7.1 (6.0)* −9.6 (5.3)** −6.2 (5.7) −6.8 (6.7) −7.8 (6.4) −9.2 (5.8)** −5.0 (6.5) −9.2 (5.3)**
CU-Q2oL Sleep Problems domain, n 49 50 48 57 62 59 61 65 60 210
 Mean (SD) −18.8 (23.5) −20.5 (21.6) −22.1 (25.4) −30.2 (23.8) −18.0 (24.2) −22.6 (23.4) −25.2 (26.4) −33.3 (24.9)** −18.3 (22.2) −29.4 (23.8)**
  1. CU-Q 2 oL Chronic Urticaria Quality of Life Questionnaire, MOS-Sleep Scale Medical Outcomes Study Sleep Scale, SPI-II Sleep Problem Index II, UPDD Urticaria Patient Daily Diary
  2. Adjusted * p < 0.05; ** p < 0.001; *** p < 0.01, versus placebo